Deferasirox

From Wikipedia, the free encyclopedia

Deferasirox
Systematic (IUPAC) name
[4-[(3Z,5E)-3,5-bis(6-oxo-1-cyclohexa-2,4- dienylidene)-1,2,4-triazolidin-1-yl]benzoic acid
Identifiers
CAS number	201530-41-8
ATC code	?
PubChem	5493381
Chemical data
Formula	C21H15N3O4
Mol. mass	373.362 g/mol
Pharmacokinetic data
Bioavailability	70%
Protein binding	99%
Metabolism	Hepatic glucuronidation
Half life	8 to 16 hours
Excretion	Fecal (84%) and renal (8%)
Therapeutic considerations
Pregnancy cat.	C(AU) B(US)
Legal status	℞-only(US)
Routes	Oral

Deferasirox (marketed as Exjade®) is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved for this purpose.

It was approved by the United States Food and Drug Administration (FDA) in November 2005.